Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial

UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians

(2014) Lei Cheng et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

(2014) M M Dias et al.   PHARMACOGENOMICS JOURNAL

Association between UGT1A1*28 Polymorphisms and Clinical Outcomes of Irinotecan-Based Chemotherapies in Colorectal Cancer: A Meta-Analysis in Caucasians

(2013) Xiang Liu et al.   PLoS One

History of Small-Cell Lung Cancer

(2011) Shadi Haddadin et al.   Clinical Lung Cancer

Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer1

(2010) Primo N. Lara et al.   CANCER

Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis

(2010) Zhe-Yi Hu et al.   EUROPEAN JOURNAL OF CANCER

A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer

(2010) Jingwei Jiang et al.   Journal of Thoracic Oncology

Camptothecins Compared with Etoposide in Combination with Platinum Analog in Extensive Stage Small Cell Lung Cancer: Systematic Review with Meta-Analysis

(2010) João Paulo S.N. Lima et al.   Journal of Thoracic Oncology

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

(2009)   GENETICS IN MEDICINE

Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review

(2009) Glenn E Palomaki et al.   GENETICS IN MEDICINE

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

(2009) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

UGT1A1*28genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan

(2009) Roberta Ferraldeschi et al.   PHARMACOGENOMICS

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study

(2008) D M Kweekel et al.   BRITISH JOURNAL OF CANCER

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

(2008) Chun-Yu Liu et al.   CANCER

Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer

(2008) Ji-Youn Han et al.   LUNG CANCER